Posted by Michael Wonder on 15 Jan 2019
Exelixis announces U.S. FDA approval of Cabometyx (cabozantinib) tablets for previously treated hepatocellular carcinoma
14 January 2019 - Approval based on statistically significant and clinically meaningful overall survival benefit demonstrated in the CELESTIAL phase 3 pivotal trial.
Exelixis today announced that the U.S. FDA approved Cabometyx (cabozantinib) tablets for patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.
HCC is the most common form of liver cancer and the fastest-rising cause of cancer-related death in the U.S.
